Login |  Register 中文

Browse By Molecule:

Your Position: Home > Antibody > Mouse MAb Antibody > Anti-Influenza A H1N1 (Swine Flu 2009) NA / Neuraminidase antibody

Anti-Influenza A H1N1 (Swine Flu 2009) NA / Neuraminidase antibodyPDF Download

Catalog Size (Price) Quantity In Stock Operation Other Information
11058-MM04

  YES       

Influenza A H1N1 (Swine Flu 2009) NA / Neuraminidase Antibody

  Order or Inquire for NA Antibody product Antibody
  Detection limit is 20 ng/lane in WB
  Detection limit is 0.16 ng/well in ELISA
 

H1N1 (Swine Flu 2009) NA Antibody Product Information

Immunogen :

Recombinant H1N1 NA protein

Antibody Type : Mouse Monoclonal Antibody ( Mouse mAb Service Platform )

Clone ID :

2F10E12G1

Ig Type :

Mouse IgG1

Formulation : 0.2 μm filtered solution in PBS with 5% trehalose
Preparation :

This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, human cell-derived, recombinant influenza A virus H1N1 Neuraminidase. The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography

H1N1 (Swine Flu 2009) NA Antibody Usage Guide

Specificity :

H1N1 (A/California/04/2009) NA / Neuraminidase

  No cross-reactivity with human cell lysate ( 293 cell line ) in WB and ELISA.
Western blot : This antibody can be used at 1 - 2 μg/mL with the appropriate secondary reagents to detect H1N1 NA in WB. Using a DAB detection system, the detection limit for H1N1 NA is approximately 20 ng/lane under reducing conditions. Use of this antibody under non-reducing conditions is not recommended
Direct ELISA : This antibody can be used at 0.5 - 1 μg/mL with the appropriate secondary reagents to detect H1N1 NA. The detection limit for H1N1 NA is 0.16 ng/well
Storage : This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

H1N1 (Swine Flu 2009) NA Antibody Related Products & Topics

Related Influenza Virus Research Tools

H1N1 (Swine Flu 2009) NA Antibody Background

Neuraminidase (NA) is a major membrane glycoproteins found on the surface of influenza virus. NA specifically catalyzes the hydrolysis removal of terminal sialic acid residues from viral and cellular glycoconjugates. It is known that HA binds to the sialic acid-containing receptors on the surface of host cells during initial infection, and at the end of an infectious cycle, NA cleaves the HA-sialic acid bondage from the newly formed virions and the host cell receptors during budding. NA thus is described as a receptor-destroying enzyme which facilitates virus release and efficient spread of the progeny virus from cell to cell. NA is a single-pass type II membrane protein which exists as a homotetramer, and the transmembrane domain is involved in lipid raft association during intracellular transport. NA is suggested to play a role in the determination of host range restriction on replication and virulence. Nine subtypes of NA have been identified, and subtypes N1 and N2 have been positively linked to epidemics in man.
Influenza A H1N1 virus is a subtype of influenza A virus. Some strains of H1N1 are endemic in humans and cause a small fraction of all influenza-like illness and a small fraction of all seasonal influenza. H1N1 strains caused a few percent of all human flu infections in 2004-2005. Other strains of H1N1 are endemic in pigs (swine influenza) and in birds (avian influenza). H1N1 was the most common cause of human influenza (flu) in 2009. In June 2009, the World Health Organization declared the new strain of swine-origin H1N1 as a pandemic. This strain is often called swine flu by the public media. This novel virus spread worldwide and had caused about 17,000 deaths by the start of 2010.

References

  1. Barman, S. et al., 2000, J. Virol. 74: 6538-45.
  2. Colman, P.M. et al., 1983, Nature. 303: 41-4.
  3. Suzuki, T. et al., 2005, J. Virol. 79: 11705-15.
  4. Shinya K, et al., 2006, Nature. 440 (7083): 435-6.
  5. von, Itzstein, M. 2007, Nat. Rev. Drug. Discov. 6: 967-74.
  6. Christophe F, et al., 2009, Science. 324:1557-61.
  7. CDC – Influenza (Flu): Weekly Report: Influenza Summary Update 20, 2004–2005 Season.